: Evidence has shown that asthmatic patients treated with short-acting beta-agonists (SABA) alone are at higher risk of life-threatening exacerbations compared to those on inhaled corticosteroids (ICS),. Given their absent anti-inflammatory properties,SABA do not treat the underlying airway inflammation and may mask disease progression,hence worsening airway hyper-responsiveness,. Global Initiative for Asthma (GINA) guidelines have recommended ICS treatment in patients with mild asthma,based on clinical studies suggesting that this cohort of patients can have severe or fatal exacerbations